<DOC>
	<DOCNO>NCT01692899</DOCNO>
	<brief_summary>To compare retention rate adalimumab , etanercept infliximab first-line biotherapy rheumatoid arthritis ( RA ) , determine cause discontinuation , retention-associated factor , retention rate possible second-line tumor necrosis factor α inhibitor ( TNFi ) .</brief_summary>
	<brief_title>Retention Rates Adalimumab , Etanercept Infliximab First Second-Line Biotherapy Patients With Rheumatoid Arthritis Daily Practice</brief_title>
	<detailed_description>In retrolective , multicentric study , medical chart RA patient start TNFi March 2005 April 2009 review , follow-up 2 6 year . The retention rate estimate use Kaplan-Meier method . Comparison TNFi do adjustment use Cox model . Factors associate good retention identify multivariate analysis . Medical chart patient RA start first TNFα inhibitor therapy March 1 , 2005 ( start commercialization adalimumab France ) April 30 , 2009 ( allow least 2 year follow-up ) systematically review detail 2 rheumatologist investigator</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>RA define 1987 ACR criterion [ 18 ] first TNFα inhibitor prescribe previously mention period TNFα inhibitor prescribe firstline biotherapy undergone least one evaluation center treatment initiation previously receive another biotherapy TNFα inhibitor prescribe RCT refuse participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Retention Rates</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Etanercept Infliximab</keyword>
	<keyword>First Second-Line Biotherapy</keyword>
	<keyword>Patients Rheumatoid Arthritis</keyword>
	<keyword>Daily Practice .</keyword>
	<keyword>TNF inhibitor</keyword>
	<keyword>biotherapy</keyword>
	<keyword>retrospective study</keyword>
</DOC>